This is the Drug That Could Kick Regeneron's Stock Into Gear Post author:Sam Post published:December 13, 2017 Post category:BioPharma Regeneron shares have made little headway since the disappointing launch of Praluent in 2015. Source: BioSpace You Might Also Like Boehringer Ingelheim Aims for 300 New Bay Area Jobs With $217 Million Expansion July 23, 2017 Stada Names Novartis Exec as New CEO, It's Fifth Leader Since 2016 January 31, 2018 Zafgen Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) October 12, 2017